The Status of Vaccine Development Against the Human Cytomegalovirus

J Infect Dis. 2020 Mar 5;221(Suppl 1):S113-S122. doi: 10.1093/infdis/jiz447.

Abstract

Numerous candidate vaccines against cytomegalovirus (CMV) infection and disease are in development. Whereas the previous article [1] provides background and opinions about the issues relating to vaccination, this article provides specifics about the vaccines in active development, as reported at a National Institutes of Health-sponsored meeting in Bethesda on September 4-6, 2018. Here, vaccine developers provide synopses of their candidate vaccines to immunize women to protect against congenital CMV disease and to prevent the consequences of CMV disease in recipients of transplanted organs or hematopoietic stem calls. The projects are presented here roughly in the descending order of their stage of development in the opinion of the first author.

Keywords: cytomegalovirus; fetal infection; organ transplant; stem cell transplant.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic
  • Cytomegalovirus / immunology*
  • Cytomegalovirus Infections / etiology*
  • Cytomegalovirus Infections / prevention & control*
  • Cytomegalovirus Vaccines / immunology*
  • Drug Evaluation, Preclinical
  • Humans
  • Organ Transplantation / adverse effects
  • Patient Outcome Assessment
  • Stem Cell Transplantation / adverse effects
  • Vaccination

Substances

  • Cytomegalovirus Vaccines